Gilead, Galapagos claim PhIIb/III win for filgotinib in ulcerative colitis — which pales in comparison to rivals
A cut of late-stage data on one of Gilead’s highest-profile experimental drugs before remdesivir made its comeback has thrusted the company back to the pre-pandemic mode of biotech — where claims of successes are necessarily scrutinized and don’t always translate to stock gains.
Gilead and its partners at Galapagos characterized the topline Phase IIb/III results for filgotinib, their oral JAK1 inhibitor, in moderately to severely active ulcerative colitis as “positive.” But a few paragraphs down, they noted that only the 200 mg achieved the clean sweep across all primary endpoints, while the 100 mg failed to induce clinical remission at week 10.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.